Comparison of the Efficacy of Sitagliptin with Pioglitazone on the Control of Diabetic Patients Blood Sugar

Abstract

We aim in this study to compare the effects of adding sitagliptin and pioglitazone to the treatment of those patients which their glycemic state is not controlled by metformin and sulfonylureas.Methods & Materials:The present study was a randomized clinical trial on the patients admitted with type II DM which were under treatment with full dose metformin (1500 to 2000 mg/day) and sulfonylureas (Glibenclamide 15 to 20 mg/day) and their diabetes was not controlled. Then, the patients were allocated into two groups with an equal number. One group received single dose pioglitazone 30 mg/day and the other received single dose sitagliptin 100 mg/day as a third medication. Fasting blood sugar (FBS), two hours postprandial blood sugar (2hpp), and HgA1C were assessed before and after three months of treatment. Variables such as age, gender, concurrent disease, weight, height, and BMI were also assessed. Then, in order to perform statistical analysis, SPSS v 24 was recruited. Results:Among 90 studied patients, 30 (33.3%) were male and 60 (66.7) were female. Mean age was 54.02 (+- 6.51) years. 45 patients (50%) were randomly received pioglitazone and 45 patients (50%) received sitagliptin. These two groups did not have significant differences in terms of demographic characteristics, FBS (p=0.248), HgA1c (p=0.605), and 2hpp (p=0.099). FBS after treatment in the sitagliptin group (131.27 +- 39.18) was higher than pioglitazone (123.47 +- 36.73); however, this difference was not statistically significant (p=0.234). HgA1c (p=0.572) and 2hpp after treatment (p=0.992) were not significantly different between groups. Mean weight after treatment in the sitagliptin group (83.14 +- 13.44 kg) was significantly less than the pioglitazone group (83.52 +- 15.8, p=0.003). pioglitazone significantly increased weight (p=0.0001). However, BMI after treatment was not significantly different between groups (p=0.816).